Myeloid Vascular Endothelial Growth Factor Expression & its Role in Tumorigenesis

Information

  • Research Project
  • 8843377
  • ApplicationId
    8843377
  • Core Project Number
    R01CA153983
  • Full Project Number
    5R01CA153983-05
  • Serial Number
    153983
  • FOA Number
    PA-10-067
  • Sub Project Id
  • Project Start Date
    1/6/2011 - 14 years ago
  • Project End Date
    12/31/2015 - 9 years ago
  • Program Officer Name
    WOODHOUSE, ELIZABETH
  • Budget Start Date
    1/1/2015 - 10 years ago
  • Budget End Date
    12/31/2015 - 9 years ago
  • Fiscal Year
    2015
  • Support Year
    05
  • Suffix
  • Award Notice Date
    12/9/2014 - 10 years ago
Organizations

Myeloid Vascular Endothelial Growth Factor Expression & its Role in Tumorigenesis

DESCRIPTION (provided by applicant): We have found that loss of Vascular Endothelial Growth Factor-A expression in myeloid cells has profound and unexpected effects in a mouse model of breast cancer. Our recent findings illustrate how inflammatory cells act to induce vascular changes in tumors, and how these changes alter tumor perfusion and oxygenation, as well as tumor cell survival and malignant progression. The work proposed here will allow us to explore and exploit these new and novel findings, in order to: determine the mechanisms of myeloid cell interactions with endothelial cells during tumor angiogenesis; better understand the relationship between myeloid cell VEGF expression and metastasis; and determine how these findings could be used to increase the efficacy of chemotherapy. The aims we propose to further our understanding of these phenomena are: 1: Determine the molecular mechanisms for differential VEGF signaling through innate immune cells in tumors. 2: Determine how VEGF expression from myeloid cells impacts metastasis. 3: Determine how VEGF from myeloid cells impacts chemotherapy delivery and efficacy. In sum, we believe this application will address key questions surrounding the processes of inflammation, angiogenesis, and tumor growth, with a particular emphasis on how these influence mammary tumorigenesis and metastasis.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R01
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
    207500
  • Indirect Cost Amount
    15003
  • Total Cost
    222503
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    396
  • Ed Inst. Type
  • Funding ICs
    NCI:222503\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    UNIVERSITY OF CAMBRIDGE
  • Organization Department
  • Organization DUNS
    226552610
  • Organization City
    CAMBRIDGE
  • Organization State
  • Organization Country
    UNITED KINGDOM
  • Organization Zip Code
    CB2 1TN
  • Organization District
    UNITED KINGDOM